Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behcet's disease

被引:22
作者
Calis, M [1 ]
Ates, F [1 ]
Yazici, C [1 ]
Kose, K [1 ]
Kirnap, M [1 ]
Demir, M [1 ]
Borlu, M [1 ]
Evereklioglu, C [1 ]
机构
[1] Erciyes Univ, Fac Med, Dept Phys Med & Rehabil, TR-38039 Kayseri, Turkey
关键词
adenosine deaminase; Behcet's disease; activity; colchicine;
D O I
10.1007/s00296-005-0612-z
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Behcet's disease (BD) is a systemic vasculitis. Although its clinical characteristics are well defined, the etiology and immune pathogenesis are not clear yet. Neutrophilic vasculitis, which is a consequence of immunological events, is suggested as the underlying pathophysiological mechanism. Adenosine deaminase (ADA) is a non-specific marker of T-lymphocyte activation. A total of 75 patients with BD (45 women and 30 men) and 25 age-matched and gender-matched healthy control volunteers (13 women and 12 men) were included in this study. BD patients were divided into three groups according to their clinical findings: inactive BD patients (group 1, n=25); active BD patients under colchicine treatment (group 2, n=25); and active BD patients without colchicine treatment (group 3, n=25). Plasma ADA (p-ADA) levels of all BD patients and the control group were measured and compared. The relationship between p-ADA levels and disease activity, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels was evaluated and correlated. Patients with BD had significantly higher p-ADA levels (20.6 +/- 6.3 U/l) than control subjects (12.8 +/- 1.8 U/l; P < 0.001). The p-ADA levels of patients with active BD were significantly (for each, P < 0.05) higher than those of inactive BD patients or controls. On the other hand, the difference was not significant (P > 0.05) between active patients with or without colchicine use. In addition, there were significantly positive correlations between p-ADA, ESR and CRP levels in patients with BD (for each, P < 0.05). However, disease duration or haemoglobin levels were not relevant. ADA level may be a valuable and supportive indicator of disease activity and is not affected by colchicine therapy in BD.
引用
收藏
页码:452 / 456
页数:5
相关论文
共 29 条
[1]
Al-Shammary FJ, 1997, BIOCHEM MOL BIOL INT, V43, P763
[2]
SERUM AND PLEURAL ADENOSINE-DEAMINASE - CORRELATION WITH LYMPHOCYTIC POPULATIONS [J].
BAGANHA, MF ;
PEGO, A ;
LIMA, MA ;
GASPAR, EV ;
CORDEIRO, AR .
CHEST, 1990, 97 (03) :605-610
[3]
Behçet H, 1937, DERMATOL WOCHENSCHR, V105, P1152
[4]
Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behcet's disease:: original contributions/clinical and laboratory investigations [J].
Erkiliç, K ;
Evereklioglu, C ;
Çekmen, M ;
Özkiris, A ;
Duygulu, F ;
Dogan, H .
MEDIATORS OF INFLAMMATION, 2003, 12 (02) :107-116
[5]
Managing the symptoms of Behcet's disease [J].
Evereklioglu, C .
EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (02) :317-328
[6]
Serum leptin concentration is increased in patients with Behcet's syndrome and is correlated with disease activity [J].
Evereklioglu, C ;
Inalöz, HS ;
Kirtak, N ;
Doganay, S ;
Bülbül, M ;
Otlu, B ;
Özerol, E ;
Er, H ;
Özbek, E .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (02) :331-336
[7]
Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease [J].
Evereklioglu, C ;
Er, H ;
Türköz, Y ;
Çekmen, M .
MEDIATORS OF INFLAMMATION, 2002, 11 (02) :87-93
[8]
Increased corneal thickness in active Behcet's disease [J].
Evereklioglu, C ;
Er, H .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2002, 12 (01) :24-29
[9]
Increased nitric oxide production in patients with Behcet's disease: Is it a new activity marker? [J].
Evereklioglu, C ;
Turkoz, Y ;
Er, H ;
Inaloz, HS ;
Ozbek, E ;
Cekmen, M .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (01) :50-54
[10]
Increased plasma adrenomedullin levels in patients with Behcet's disease [J].
Evereklioglu, C ;
Yurekli, M ;
Er, H ;
Ozbek, E ;
Hazneci, E ;
Cekmen, M ;
Inaloz, HS .
DERMATOLOGY, 2000, 201 (04) :312-315